Antifungal therapeutic drug monitoring

被引:23
作者
Lewis R.E. [1 ]
机构
[1] University of Houston College of Pharmacy, University of Texas M.D. Anderson Cancer Center, Texas Medical Center Campus, Houston, TX 77030
关键词
Antifungal agents; Antifungals; Fungal infections; Itraconazole; Pharmacokinetics; Pharmacology; Posaconazole; TDM; Therapeutic drug monitoring; Triazoles; Voriconazole;
D O I
10.1007/s12281-010-0023-9
中图分类号
学科分类号
摘要
A growing body of evidence suggests that patient-to-patient variability in the pharmacokinetics of some antifungals, particularly the mold-active triazoles (itraconazole, voriconazole, and posaconazole) may contribute to therapeutic failure or unexpected toxicity. As a result, many clinicians have recognized a need for therapeutic drug monitoring (TDM) to individualize drug dosing in select patients with suspected or documented invasive fungal infections. However, approaches for performing and interpreting plasma concentrations are not well standardized, and logistical issues such as the turnaround time of test results can limit the clinical usefulness of testing in acutely ill patients. This article summarizes the pharmacologic rationale for TDM of antifungal agents, with a particular focus on recently published data for the newer triazoles, voriconazole and posaconazole. Practical recommendations for TDM-guided dosing are also provided, based on a critical evaluation of literature published over the past 5 years. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码:158 / 167
页数:9
相关论文
共 76 条
  • [1] Andes D., Pascual A., Marchetti O., Antifungal therapeutic drug monitoring: Established and emerging indications, Antimicrob Agents Chemother, 53, pp. 24-34, (2009)
  • [2] Lewis R.E., What is the "therapeutic range" for voriconazole?, Clin Infect Dis, 46, pp. 212-214, (2008)
  • [3] Schumacher G.E., Introduction to therapeutic drug monitoring, Therapeutic Drug Monitoring, pp. 1-17, (1995)
  • [4] Walsh T.J., Teppler H., Donowitz G.R., Et al., Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, pp. 1391-1402, (2004)
  • [5] Walsh T.J., Pappas P., Winston D.J., Lazarus H.M., Petersen F., Raffalli J., Yanovich S., Stiff P., Greenberg R., Donowitz G., Schuster M., Reboli A., Wingard J., Arndt C., Reinhardt J., Hadley S., Finberg R., Laverdiere M., Perfect J., Garber G., Fioritoni G., Anaissie E., Lee J., Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever, New England Journal of Medicine, 346, 4, pp. 225-234, (2002)
  • [6] Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., Pappas P., Seibel N., Greenberg R.N., Dummer S., Schuster M., Holcenberg J.S., Dismukes W.E., Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropenia, New England Journal of Medicine, 340, 10, pp. 764-771, (1999)
  • [7] Drutz D.J., Spickard A., Rogers D.E., Koenig M.G., Treatment of disseminated mycotic infections: A new approach to amphotericin B therapy, Am J Med, 45, pp. 405-418, (1968)
  • [8] Hong Y., Shaw P.J., Nath C.E., Yadav S.P., Stephen K.R., Earl J.W., McLachlan A.J., Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases, Antimicrobial Agents and Chemotherapy, 50, 3, pp. 935-942, (2006)
  • [9] Brammer K.W., Farrow P.R., Faulkner J.K., Pharmacokinetics and tissue penetration of fluconazole in humans, Reviews of Infectious Diseases, 12, SUPPL. 3, (1990)
  • [10] Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., Lancaster M., Odds F.C., Rinaldi M.G., Walsh T.J., Barry A.L., Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections, Clinical Infectious Diseases, 24, 2, pp. 235-247, (1997)